|
| Overall Recruitment Status: Active, currently enrolling |
| |
| Official Title |
| A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata. |
| |
| Region |
Sponsors |
| California - Northern |
|
| |
| Acronym |
KP IRB No. |
| CTP-543 |
1405545 |
| |
| Study Type |
Phase |
| Clinical Trial |
Phase II |
| |
| Study Population Description |
| (Adult, Older Adult) Male and Female with Alopecia Areata. |
| |
| Purpose |
| The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
|
| |
| Detailed Description |
|
|
| |
| Gender |
Age Limit |
| Male & Female |
18 - 65 years |
| |
- Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial
|
- Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis
|
-
Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study medication
|
-
Donation of blood at any point throughout the study and for 30 days after last dose of study medication
|
|
| |
|
|
-
Pathological Conditions, Anatomical
|
|
|
|
|
|
|
|
|
|
|
| |
|
| |
|